Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | BCL9 | O00512 | 4/20 | 0.37 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23456316 | 1.00 | EPHX2 (0.40) | EPHX2CYP1A2PIK3CDPIK3CAPIK3CB | |
| SCHEMBL23456315 | 1.00 | EPHX2 (0.40) | EPHX2CYP1A2PIK3CDPIK3CAPIK3CB | |
| SCHEMBL22265669 | 0.86 | PIK3CD (0.45) | EPHX2CYP1A2PIK3CDPIK3CAPIK3CB | |
| SCHEMBL22265757 | 0.86 | PIK3CD (0.45) | EPHX2CYP1A2PIK3CDPIK3CAPIK3CB | |
| SCHEMBL28694105 | 0.86 | PIK3CD (0.45) | EPHX2CYP1A2PIK3CDPIK3CAPIK3CB | |
| SCHEMBL30392239 | 0.85 | GPR119 (0.46) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL30391125 | 0.85 | GPR119 (0.46) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL20658806 | 0.82 | EPHX2 (0.47) | EPHX2OPRK1KMT2A | |
| SCHEMBL20165095 | 0.81 | KMT2A (0.46) | EPHX2KMT2A | |
| SCHEMBL20165094 | 0.81 | KMT2A (0.46) | EPHX2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542254-B2 | Methods and composition of 4-substituted benzoylpiperazine-1-substituted carbonyls as beta-catenin/B-cell lymphoma 9 inhibitors | UNIVERSISITY OF UTAH RESEARCH FOUNDATION (US) | 2023-01-03 | — | — | US | disclosed |
| US-20210171502-A1 | METHODS AND COMPOSITION OF 4-SUBSTITUTED BENZOYLPIPERAZINE-1-SUBSTITUTED CARBONYLS AS BETA-CATENIN/B-CELL LYMPHOMA 9 INHIBITORS | UNITED STATES GOVERNMENT | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171502-A1 | METHODS AND COMPOSITION OF 4-SUBSTITUTED BENZOYLPIPERAZINE-1-SUBSTITUTED CARBONYLS AS BETA-CATENIN/B-CELL LYMPHOMA 9 INHIBITORS | BCL9, BCL9L, BCL3 | EPHX2 3499/4885CYP1A2 2886/4885PIK3CD 990/4885 |
| US-11542254-B2 | Methods and composition of 4-substituted benzoylpiperazine-1-substituted carbonyls as beta-catenin/B-cell lymphoma 9 inhibitors | BCL9, BCL9L, BCL3 | EPHX2 3528/4885CYP1A2 2466/4885PIK3CD 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.